Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Gordon Joyce

Showing results (71-80 of 109) with videos related to

Pageof 11
Sort By:
Cell Host & Microbe|March 4, 2021
B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodiesSamantha M Townsley, Gina C Donofrio, Ningbo Jian, et al.
Mbio|August 29, 2025
First-generation N-terminal domain supersite public antibodies retain activity against Omicron-derived lineages and protect mice against Omicron BA.5 challengeVincent Dussupt, Jaime L Jensen, Paul V Thomas, et al.
Journal of Virology|July 3, 2023
Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus ActivityJaime L Jensen, Rajeshwer S Sankhala, Vincent Dussupt, et al.
Immunity|May 18, 2017
Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding LoopEvan M Cale, Jason Gorman, Nathan A Radakovich, et al.
The Lancet. Microbe|May 18, 2024
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trialBrittany L Ober Shepherd, Paul T Scott, Jack N Hutter, et al.
Immunity|August 6, 2013
Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodiesTongqing Zhou, Jiang Zhu, Xueling Wu, et al.
Immunity|November 17, 2016
Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization BreadthJinghe Huang, Byong H Kang, Elise Ishida, et al.
Cell Reports|December 28, 2017
Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal ModelsKevin O Saunders, Laurent K Verkoczy, Chuancang Jiang, et al.
Science (New York, N.Y.)|May 14, 2016
Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibodyRui Kong, Kai Xu, Tongqing Zhou, et al.
Iscience|October 1, 2024
SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activityElizabeth J Martinez, William C Chang, Wei-Hung Chen, et al.
Pageof 11

Showing results (71-80 of 109) with videos related to

Sort By:
Pageof 11
Cell Host & Microbe|March 4, 2021
B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodiesSamantha M Townsley, Gina C Donofrio, Ningbo Jian, et al.
Mbio|August 29, 2025
First-generation N-terminal domain supersite public antibodies retain activity against Omicron-derived lineages and protect mice against Omicron BA.5 challengeVincent Dussupt, Jaime L Jensen, Paul V Thomas, et al.
Journal of Virology|July 3, 2023
Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus ActivityJaime L Jensen, Rajeshwer S Sankhala, Vincent Dussupt, et al.
Immunity|May 18, 2017
Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding LoopEvan M Cale, Jason Gorman, Nathan A Radakovich, et al.
The Lancet. Microbe|May 18, 2024
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trialBrittany L Ober Shepherd, Paul T Scott, Jack N Hutter, et al.
Immunity|August 6, 2013
Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodiesTongqing Zhou, Jiang Zhu, Xueling Wu, et al.
Immunity|November 17, 2016
Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization BreadthJinghe Huang, Byong H Kang, Elise Ishida, et al.
Cell Reports|December 28, 2017
Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal ModelsKevin O Saunders, Laurent K Verkoczy, Chuancang Jiang, et al.
Science (New York, N.Y.)|May 14, 2016
Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibodyRui Kong, Kai Xu, Tongqing Zhou, et al.
Iscience|October 1, 2024
SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activityElizabeth J Martinez, William C Chang, Wei-Hung Chen, et al.
Pageof 11